Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.63    
  

April 10,
2001 

Vince,
Morris

23 Coleport Landing

Alameda, CA 94502 

Dear
Vince, 

    Following
the close of our 2000 business, the development of our 2001 plan and our recent discussions, it is with pleasure that I confirm our verbal offer for your continued
employment with QRS Corporation. The following summarizes our offer: 

POSITION  

    You will have overall corporate responsibility for Senior Vice President, Support and Operations. You are a member of the Corporate Management Committee and
you may attend Board of Directors meetings as required and at the invitation of the Board. 

REPORTING TO  

    John Simon, CEO 

LOCATION  

    Richmond, CA 

MISSION STATEMENT  

    As a key executive of QRS, you should ensure continued focus on the long-term mission of QRS: 

	•
	QRS
is a leading worldwide provider of collaborative business-to-business E-commerce solution for the retail industry.

	•
	Through
the Tradeweave Retail network, we offer an integrated suite of network and service platforms that enhance the profitability and efficiency of
relationships between business across the global retail supply chain

	•
	We
will exceed customer expectations for service quality

	•
	We
will be recognized as an exciting and rewarding place to work by our employees

	•
	We
will provide superior returns to our shareholders 

    Finally,
as a key executive of QRS, you also have as continuing, significant responsibility the development and maintenance of QRS' management process and promotion of and adherence
to its core values among its associates 

KEY OBJECTIVES  

    As a key executive of QRS, your focus in 2001 should be on successfully addressing the critical issues required for QRS to exceed our financial plan. Your
objectives will be detailed in the 2001 Annual Incentive Compensation Plan. (See Addendum A) 

ANNUAL COMPENSATION  

    Your annual compensation will be administered by me and reviewed by the Compensation Committee of the Board of Directors. 

	•
	Your
base compensation will be $200,000 per year. 

	•
	In
addition, your targeted annual incentive compensation will be $100,000 or 50% of your base compensation. For details of your incentive compensation
plan, please refer to Addendum A.

	•
	Therefore,
the annual total target compensation (base plus incentive at 100% of plan) shall be $300,000. 

    Your
compensation will be reviewed at the first day of the quarter immediately following the second quarter in which the company is on its financial plan and budget. (i.e. if the
company reaches its correct financial plan by Q1, your compensation will be reviewed on the first day of Q3) 

    Otherwise,
your compensation including incentives, will be reviewed in the first quarter of each year (unless there is a change in objectives, locations, etc., in which case it will
be reviewed at that time), to ensure that it continues to be equitable, appropriate to the location and provide appropriate incentives and support to the agreed objectives. 

LONG TERM INCENTIVES  

    As an officer of QRS, on January 2, 2001, you were entitled to convert your stock options into restricted QRS stock. If you elected to convert your
stock options into restricted shares, the restricted shares will have the same provisions as your original stock options with the exception of a different vesting schedule as outlined in your
Restricted Stock Agreement (i.e. acceleration, change of control protection, etc.). The Board of Directors may grant you more stock options in the future with the approval of the Compensation
Committee. The details of your current stock option grants and restricted stock is attached in Addendum B. 

BENEFITS  

    In addition to the benefits available to all QRS associates as defined in the Employee Handbook; as a Senior Vice President and Officer you are provided with
additional benefits as follows: 

    Disability
Insurance—The Company shall purchase and maintain in effect disability insurance sufficient to provide you with an income equal to 66% of your base compensation
while you are disabled and unable to perform the duties of your current employment with QRS. You will have the option of continuing this additional disability insurance coverage at your own expense in
the event of the termination of your employment. This additional insurance benefit is taxable and will be reported for tax purposes as additional income to you. 

    Liability
Insurance—The Company shall purchase and maintain in effect sufficient Officer's liability insurance to provide you with reasonable coverage, including the
provision of legal counsel and/or reimbursement of appropriate legal fees you pay personally, against all liability claims and judgments arising from your legal exercise of your duties as an Officer
of QRS, including any actions filed after you cease your duties as an Officer or in the event of the termination of your employment. The Company shall also provide in its bylaw as full indemnification
for you as a QRS officer to the maximum extent permissible under Delaware law. 

TERMINATION AND SEVERANCE  

    This position is for no set period or term and just as you have the right to resign your position, at any time, for any reason, QRS reserves the right to
terminate your employment, at any time, with or without cause, with or without notice. 

    In
the event your employment is terminated without cause, you will become entitled to twelve (12) months of severance pay equal in the aggregate to your targeted total annual
compensation and benefits at the level in effect at the time of your termination. Your severance payments will be made in accordance with the Company's standard payroll practices for current employees
and will be subject to the Company's collection of all applicable withholding taxes. 

    For
purposes of this agreement, termination "for cause" shall mean a termination of your employment for any of the following reasons: (1) your failure to substantially perform
the material 

duties of your position with the Company after a written demand for substantial performance is delivered to you by the Company which specifically identifies the manner in which you have not
substantially performed those duties and which provides a reasonable period for you to cure those deficiencies; (2) a material breach by you of your obligations under any confidential or
proprietary information agreements with the Company or of any of your fiduciary obligations as an officer of the Company, (3) your failure to follow in a material respect the reasonable
policies or directives established on an employee-wide basis by the Company, after written notice to you indicating the policies or directives with which you are not in material
compliance, (4) any willful misconduct on your part having a material detrimental effect on the Company or (5) any unauthorized activity on your part which creates a material conflict of
interest between you and the Company after you have been provided with a reasonable opportunity to refrain from that activity. 

    In
the event you resign your employment you will be entitled to all salary, wages and accrued vacation and any other group health benefits due through the date of your resignation.
You will not be entitled to any unpaid annual incentive compensation. Additionally, any stock options granted or restricted shares awarded to you that have not vested by the date of your resignation
shall terminate. 

CHANGE OF CONTROL BENEFITS  

    Should there occur a Corporate Transaction or a Change in Control (as those terms are defined in the Company's 1993 Stock Option/Stock Issuance Plan) and
either (i) your employment is subsequently terminated without cause or (ii) you subsequently resign by reason of a material change in your base compensation, your targeted annual
incentive compensation, your annual total target compensation, or your benefits (for this purpose, 15% will be deemed a material reduction), a material reduction in your duties or responsibilities, or
a change in your principal place of employment by more than 50 miles, then your QRS stock options and restricted shares shall immediately vest in full. Also, you will be entitled to twelve
(12) months of severance pay equal in the aggregate to your targeted total annual compensation and benefits at the level in effect at the time of your termination or resignation or (if greater)
at the level in effect immediately prior to the Corporate Transaction or Change in Control. Your severance payments will be made in accordance with the Company's standard payroll practices for current
employees and will be subject to the Company's collection of all applicable withholding taxes. 

    Alternatively,
if there is a change of control of the Company (as defined in the stock option plan) and within 12 months of such change of control, either (i) your
employment is terminated other than for cause, as defined above, or (ii) there is a material reduction in salary, (for this purpose, 15% will be deemed a material reduction), or a material
reduction in your responsibility and as a result you choose to resign, you will be paid the base compensation and benefits for a further 12 months from the time of such reduction and your share
option (s) or restricted stock will vest in full. In addition, should there be a change in control prior to the full vesting of your share grant (s) or restricted stock, following which
change in control you remain employed by the successor corporation for a period of 12 months, the unvested shares subject to that option or restricted stock will accelerate and vest in full
12 months following the date of the change in control. 

EMPLOYMENT AT WILL  

    As you may be aware California is an Employment At Will state. This means that your position is for no set
period or term and just as you have the right to resign your position, at any time, for any reason, QRS reserves the right to terminate your employment, at any time, with or without cause and with or
without notice. If any contrary representation has been made to you, it is superseded by this letter. No subsequent agreement contrary to this nor any amendment to this term can be made unless it is
in writing and signed by both you and the VP, Human Resources. 

Sincerely,

	/s/ JOHN SIMON   
 John Simon, CEO

	 

    I
accept this ongoing position with QRS Corporation on these terms and conditions on the terms above and understand and agree that it supersedes any other agreement, written or oral,
I may have with QRS with respect to employment or compensation by QRS including salary, incentive, options, termination and severance. 

	/s/ VINCE MORRIS   
 Vince Morris	 	5/08/01
 Date

QuickLinks

Exhibit 10.63<PAGE>

                                                                  Execution Copy

                      ACCESS, OPTION AND LICENSE AGREEMENT

      This Access, Option and License Agreement (the "Agreement") effective the
30th day of March 2001 (the "Effective Date"), is made by and between ImmunoGen
Inc., a Massachusetts corporation ("ImmunoGen"), with a principal place of
business at 128 Sidney Street, Cambridge, Massachusetts 02139, and Millennium
Pharmaceuticals, Inc., a Delaware corporation ("Millennium"), with a principal
place of business at 75 Sidney Street, Cambridge, Massachusetts 02139.

                                   BACKGROUND

      A. ImmunoGen controls certain cytotoxic compounds and certain technologies
relating to the conjugation of such cytotoxic compounds to antibodies.

      B. Millennium desires to access and evaluate such cytotoxic compounds and
technologies in connection with antibodies controlled by Millennium.

      C. Millennium also desires to obtain from ImmunoGen the right to
exclusively option and/or exclusively license such cytotoxic compounds and
technologies for use with antibodies that interact with specific antigens.

      D. ImmunoGen is willing to grant the foregoing rights to Millennium on the
terms and conditions set forth in this Agreement.

      NOW, THEREFORE, ImmunoGen and Millennium agree as follows:

1. DEFINITIONS

      1.1 [ * ] shall mean any product containing an [ * ] with any [ * ] shall
be distinguished from other [ * ] based on both the [ * ] used in the [ * ] and
the [ * ] to the [ * ].

      1.2 "Access Term" shall mean the term identified in Section 2.1 of this
Agreement.

      1.3 "Adverse Event" shall mean, with respect to a patient or subject who
is administered an AB-Cytotoxic Product, a "serious adverse experience" or
"unexpected adverse experience," each as defined in the regulations promulgated
by the United States Food and Drug Administration, or any foreign equivalent
thereof, to the extent related to the Cytotoxic Compound that comprises the
AB-Cytotoxic Product.

      1.4 "Affiliate" shall mean any entity which controls, is controlled by or
is under common control with a Party. An entity shall be regarded as in control
of another entity if it owns or controls

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

<PAGE>

at least fifty percent (50%) of the shares of the subject entity entitled to
vote in the election of directors or, in the case of an entity that is not a
corporation, for the election of the corresponding managing authority.

      1.5 "Antibody" or "AB" shall mean a composition comprising a whole
antibody or fragment thereof (whether polyclonal or monoclonal, multiple or
single chain, recombinant, transgenic animal derived or naturally occurring, and
any constructs thereof) or having been derived from nucleotide sequences
encoding, or amino acid sequences of, such an antibody or fragment.

      1.6 "BLA" shall mean a Biologics License Application, as defined in the
regulations promulgated by the United States Food and Drug Administration, or
any foreign equivalent thereof.

      1.7 "Confidential Information" shall mean, with respect to a Party, all
information of any kind whatsoever (including without limitation, compilations,
data, formulae, models, patent disclosures, procedures, processes, projections,
protocols, results of experimentation and testing, specifications, strategies
and techniques), and all tangible and intangible embodiments thereof of any kind
whatsoever (including without limitation, apparatus, biological or chemical
materials, animals, cells, compositions, documents, drawings, machinery, patent
applications, records and reports), which is owned or controlled by such Party
and is marked as confidential at the time of disclosure to the receiving Party
or of a type that is customarily considered to be confidential information.
Notwithstanding the foregoing, the receiving Party shall be entitled to use and
disclose Confidential Information which (a) was known or used by the receiving
Party or its Affiliates prior to its date of disclosure to the receiving Party
as demonstrated by legally admissible evidence available to the receiving Party
or its Affiliates, (b) either before or after the date of the disclosure to the
receiving Party is lawfully disclosed to the receiving Party or its Affiliates
by sources other than the disclosing Party rightfully in possession of the
Confidential Information, (c) either before or after the date of the disclosure
to the receiving Party becomes published or otherwise part of the public domain
through no fault or omission on the part of the receiving Party or its
Affiliates, or (d) is independently developed by or for the receiving Party or
its Affiliates without reference to or in reliance upon the Confidential
Information as demonstrated by competent written records.

      1.8 "Control" or "Controlled" shall mean (a) with respect to know-how
(other than tangible materials) and/or Patent Rights, the possession by a Party
of the ability to grant a license or sublicense of such know-how and/or Patent
Rights as provided herein without violating the terms of any agreement or
arrangement between such Party and any Third Party and (b) with respect to
tangible materials, the possession by a Party of the ability to supply such
materials to the other Party as provided herein without violating the terms of
any agreement or arrangement between such Party and any Third Party.

      1.9 "Control Antibody" shall have the meaning set forth in [ * ] of this
Agreement.

      1.10 [ * ] shall mean any [ * ], Controlled by ImmunoGen, including,
without limitation, [ * ] shall also include [

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       2
<PAGE>

* ]. As used in [ * ] of this Agreement, one [ * ] shall [ * ] and [ * ].

      1.11 [ * ] shall mean the [ * ] of [ * ] including, without limitation,
the sum of the following components: (a) the [ * ]; (b) all [ * ] to the [ * ]
under the foregoing clause (a), including, without limitation, [ * ] which are [
* ] based on [ * ]; (c) any other costs borne by ImmunoGen for the [ * ]; and
(d) [ * ] which are [ * ] or [ * ] or [ * ].

      1.12 [ * ] shall mean (a) if [ * ] or (b) if [ * ], including, without
limitation, the sum of the following components: (a) [ * ]; (b) [ * ] to the [ *
] under the foregoing clause (a), including, without limitation, [ * ] which are
[ * ]; (c) [ * ] for the [ * ]; and (d) [ * ] which are [ * ] on [ * ].

      1.13 "Evaluation Agreement" shall mean the Evaluation and Option Agreement
between the Parties dated March 1, 2001.

      1.14 "Exclusive License" shall mean an [ * ] by ImmunoGen to Millennium
with respect to a [ * ] pursuant to [ * ] of this Agreement.

      1.15 "First Exclusive Option" shall have the meaning given such term in
Section 3.1 of this Agreement.

      1.16 "Exclusive Option" shall mean an exclusive option granted by
ImmunoGen to Millennium with respect to a Target Antigen pursuant to Section 3.4
of this Agreement.

      1.17 "cGLPs" shall have the meaning set forth in Section 5.3 of this
Agreement.

      1.18 "ImmunoGen Know-How" shall mean all information, including without
limitation, any process or protocol, whether or not patentable, Controlled by
ImmunoGen during the term of this Agreement, which is necessary or useful to
manufacture Cytotoxic Compounds, to develop, conjugate, manufacture, use,
import, distribute and/or sell AB-Cytotoxic Compounds or to use ImmunoGen
Materials.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       3
<PAGE>

      1.19 "ImmunoGen Materials" shall mean Cytotoxic Compounds and any other
materials, including without limitation, any assays or antibodies, whether or
not patentable, Controlled by ImmunoGen during the term of this Agreement, which
are necessary or which the Parties mutually agree are useful to manufacture
Cytotoxic Compounds or to develop, conjugate, manufacture, use, import,
distribute and/or sell AB-Cytotoxic Compounds.

      1.20 "ImmunoGen Patent Rights" shall mean all Patent Rights Controlled by
ImmunoGen during the term of this Agreement which claim any ImmunoGen Know-How
or ImmunoGen Materials. ImmunoGen Patent Rights as of the Effective Date are
listed on Attachment A.

      1.21 "Improvement" shall mean any improvement, enhancement or modification
directly relating to ImmunoGen's general manufacturing process for Cytotoxic
Compounds or ImmunoGen's general conjugation and/or manufacturing process for
AB-Cytotoxic Compounds.

      1.22 "IND" shall mean an Investigational New Drug Application, as defined
in the regulations promulgated by the United States Food and Drug
Administration, or any foreign equivalent thereof.

      1.23 "Liabilities" shall have the meaning set forth in Section 9.1 of this
Agreement.

      1.24 "Licensed Technology" shall mean ImmunoGen Know-How and/or ImmunoGen
Patent Rights.

      1.25 "Manufacturing Committee" shall have the meaning given such term in
Section 5.15 of this Agreement.

      1.26 "Millennium Antibody" shall have the meaning set forth in Section 2.3
of this Agreement.

      1.27 "Millennium Invention" shall mean (a) any invention made, conceived,
reduced to practice or otherwise developed by Millennium in the conduct of
activities under this Agreement and (b) any AB-Cytotoxic Product conjugated by
ImmunoGen that incorporates a Millennium Antibody or Control Antibody.
Notwithstanding the foregoing, Millennium Inventions shall not include
Improvements.

      1.28 "Millennium Know-How" shall mean any information and materials,
whether or not patentable, developed by Millennium in the conduct of activities
under this Agreement including, without limitation, any and all laboratory,
preclinical and clinical data pertaining to AB-Cytotoxic Product.
Notwithstanding the foregoing, Millennium Know-How shall not include
Improvements.

      1.29 "Millennium Materials" shall mean a Millennium Antibody or Control
Antibody and any nucleotide sequences, genes, amino acid sequences, cells,
hybridomas or other biological materials and information relating to such
Millennium Antibody or Control Antibody or to the Target Antigen with which such
Millennium Antibody or Control Antibody interacts.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       4
<PAGE>

      1.30 "Millennium Patent Rights" shall mean all Patent Rights Controlled by
Millennium during the term of this Agreement which claim a Millennium Invention.

      1.31 "Millennium Target Antigen" shall mean a Target Antigen that
ImmunoGen has informed Millennium is available under Section 3.3 or Section 4.3
of this Agreement and to which [ * ] to Millennium by ImmunoGen under an [ * ].

      1.32 "NDA" shall mean a New Drug Application, as defined in the
regulations promulgated by the United States Food and Drug Administration, or
any foreign equivalent thereof.

      1.33 "[ * ]" shall mean the [ * ] amount [* ] by [ * ] and [ * ] on [ * ]
or other [ * ] of [ * ] to [ * ] the [ * ] of (a) [ * ], (b) [ * ], (c) [ * ]
directly related to the [ * ], (d) [ * ] on the [* ] or [ * ] of [ * ]
(including any [ * ] such as a [ * ] or similar [ * ]) borne by the [ * ]
thereof, other than [ * ] of any kind whatsoever, and (e) [ * ] given or made
for [ * ].

In the event that an [ * ] is [ * ] in the form of a [ * ] containing [ * ] in
addition to the [ * ] and the [ * ] included in such [ * ], [ * ] of such [ * ]
will be [ * ] of such [ * ] in such [ * ] by the [ * ], where [*] is the [ * ]
of the [ * ] in such [ * ], if [ * ] in such [ * ], and [*] is the [ * ] of any
other [ * ] in the [* ] in such [ * ], if [ * ] in such [ * ]. If, in a [ * ],
either the [ * ] or the [ * ] are [ * ] in such [ * ], the [ * ] shall [ * ] an
[ * ] with respect to such [ * ]. If the [ * ] are [ * ] such an [ * ] with
respect to [ * ] within [* ] of the [* ] of any such [ * ], then, unless the [ *
] to an [ * ] of such time [ * ], [ * ] shall have the [ * ] in accordance with
[ * ].

      1.34 "Party" shall mean ImmunoGen or Millennium; "Parties" shall mean
ImmunoGen and Millennium.

      1.35 "Phase I Clinical Trials" shall mean a clinical study in subjects to
evaluate the pharmacokinetic and pharmacodynamic properties, maximum tolerated
dose, dosing interval, and absorption, distribution, metabolism and excretion of
an AB-Cytotoxic Product.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       5
<PAGE>

      1.36 "Phase II Clinical Trials" shall mean (a) a dose exploration, dose
response, duration of effect and preliminary efficacy and safety clinical trial
of an AB-Cytotoxic Product in a target population or (b) a controlled dose
ranging clinical trial to evaluate further the efficacy and safety of an
AB-Cytotoxic Product in a target population and to define the optimal dosing
regimen.

      1.37 "Phase III Clinical Trials" shall mean a controlled clinical trial to
confirm with statistical significance the efficacy and safety of an AB-Cytotoxic
Product in larger target patient populations and performed in order to obtain
regulatory approval of an AB-Cytotoxic Product.

      1.38 "Phase III Equivalent Date" shall mean the later of (a) the date on
which Millennium has received notice from the United States Food and Drug
Administration that the data produced during Phase II Clinical Trials of an
AB-Cytotoxic Product is sufficient to support the filing of a BLA or NDA and (b)
the date on which Millennium decides to proceed with the filing of a BLA or NDA
in lieu of conducting Phase III Clinical Trials on such AB-Cytotoxic Product.

      1.39 "Patent Rights" shall mean the rights and interests in and to issued
patents and pending patent applications, without limitation to any country,
including, but not limited to, all provisional applications, substitutions,
continuations, continuations-in-part, divisions, and renewals, all letters
patent granted thereon, and all reissues, reexaminations and extensions thereof,
and supplemental protection certificates relating thereto Controlled by a Party.

      1.40 "Preclinical Research" shall mean the conduct of laboratory research
and/or the conduct of preclinical safety and/or efficacy and/or toxicology
studies in vitro and/or in vivo in any non-human species including, without
limitation, IND enabling studies.

      1.41 [" * "] shall have the meaning set forth in [ * ] hereof.

      1.42 "Target Antigen" shall mean any protein, peptide, carbohydrate or
other composition with which a particular AB interacts, or any fragment, peptide
or epitope thereof.

      1.43 "Third Party" shall mean any entity other than ImmunoGen or
Millennium or their respective Affiliates.

      1.44 "Third Party Patents" shall mean an issued, unexpired patent that is
Controlled by a Third Party which patent has at least one Valid Claim that (a)
claims any Cytotoxic Compound, the use of any Cytotoxic Compound to conjugate
and/or manufacture AB-Cytotoxic Product, or any other invention which is
necessary for the conjugation and/or manufacture of AB-Cytotoxic Products and
(b) would be infringed by the development, conjugation, manufacture, use,
import, distribution and/or sale of AB-Cytotoxic Products by Millennium but for
Millennium obtaining a license under such patent.

      1.45 "Valid Claim" shall mean a claim in an unexpired patent which has not
been held unenforceable, unpatentable or invalid by a decision of a court or
other government agency of competent jurisdiction, which is unappealable or
unappealed within the time allowed for appeal,

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       6
<PAGE>

which has not been admitted to be invalid or unenforceable through reissue,
reexamination or disclaimer, and which is not subject to an interference action.

2. ACCESS RIGHTS

      2.1 Term. The term during which Millennium shall have access to the
Licensed Technology under the terms of this Agreement shall be for a period of
five (5) years commencing on the Effective Date (the "Access Term"), provided
that Millennium shall have the right, in its sole discretion, to extend the
Access Term for an additional three (3) years upon written notification to
ImmunoGen made prior to the fifth anniversary of the Effective Date.

      2.2 Access Fees. Upon execution of this Agreement, Millennium shall pay to
ImmunoGen an access fee for the initial five-year term equal to Two Million
Dollars ($2,000,000) In the event that Millennium elects to extend the Access
Term for the additional three-year term, Millennium shall pay to ImmunoGen an
extension fee equal to [ * ] in the [ * ] to have in effect, [ * ] (as described
in [ * ] of this Agreement) [ * ] to have in effect, [ * ] (as described in [ *
] of this Agreement).

      2.3 Access License. ImmunoGen hereby grants to Millennium a non-exclusive,
worldwide, royalty-free license under the Licensed Technology for the purpose of
conducting Preclinical Research, during the Access Term, with any AB-Cytotoxic
Product that interacts with a Target Antigen that is [ * ] existing as of the
Effective Date from ImmunoGen to a Third Party, which AB-Cytotoxic Product shall
contain Antibodies Controlled by Millennium (each, a "Millennium Antibody") or
Antibodies selected by Millennium for experimental control purposes (each, a
"Control Antibody"). The license grant set forth in this Section 2.3 shall
include the right to grant sublicenses to (a) [ * ], (b) [ * ] who [ * ] and (c)
[ * ] who are [ * ] of [ * ] with respect to the [ * ] containing [ * ]. For
purposes of clarity, the license grant set forth in this Section 2.3 shall
include the right to access ImmunoGen Materials in accordance with Section 5.14
hereof for the purpose of conducting Preclinical Research on AB-Cytotoxic
Products containing Millennium Antibodies.

      2.4 Right to Supply. During the [ * ], ImmunoGen shall [ * ] to [ * ]
Millennium with [ * ] of [ * ] for the purpose of conducting [ * ] in accordance
with Section 2.3 this Agreement. The terms of [ * ] of this Agreement shall
govern [ * ] of such [ * ]. Alternatively, during the [ * ], Millennium shall
have the right, and ImmunoGen hereby grants to Millennium a non-exclusive,
worldwide, royalty-free license under the Licensed Technology, to [ * ] of [ * ]
for the purpose of conducting Preclinical Research in accordance with Section
2.3 of this Agreement. For purposes of clarity, the [ * ] set forth in this [ *
] shall include [ * ] to [ * ] in accordance with [ * ] hereof for the purpose
of [ * ] in accordance with this [ * ]. The license grant set forth in [

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       7
<PAGE>

* ] shall include [ * ] to [ * ] to [ * ] and [ * ] who [ * ] on [ * ] of
Millennium.

      2.5 Use of Cytotoxic Compound, Other ImmunoGen Materials and AB-Cytotoxic
Product. In connection with the licenses set forth in Section 2.3 and Section
2.4, Millennium hereby agrees that it (a) shall not use the Cytotoxic Compounds,
other ImmunoGen Materials and/or AB-Cytotoxic Products in any human subject, (b)
shall use the Cytotoxic Compounds, other ImmunoGen Materials and/or AB-Cytotoxic
Products in compliance with all applicable federal, state and local laws and
regulations, and (c) as a matter of contract between itself and ImmunoGen, shall
assume all liability for damages that may arise from the use, storage and
disposal of any Cytotoxic Compounds, other ImmunoGen Materials and/or
AB-Cytotoxic Products. Millennium shall be entitled to transfer Cytotoxic
Compounds, other ImmunoGen Materials and/or AB-Cytotoxic Products to a Third
Party (pursuant to the terms of Section 2.3 or Section 2.4 of this Agreement)
under terms obligating such Third Party not to transfer or use such Cytotoxic
Compounds and/or AB-Cytotoxic Products except in compliance with the foregoing
clauses (a) through (c) of this Section 2.5.

3. EXCLUSIVE OPTIONS

      3.1 Availability of Exclusive Options. During the Access Term, Millennium
shall have the right to have in effect, at any given time, up to [ * ] to obtain
an [ * ] with respect to a [ * ] as further described in [ * ] of this Agreement
(each, an "[ * ]"). For purposes of making such calculation, [ * ] that have
been [ * ] shall not be [ * ] as being [ * ]. The Parties hereby acknowledge
that, under the terms of the [ * ], Millennium [ * ] for the [ * ] and that, [ *
] the terms of [ * ].

      3.2 Procedure to Obtain Exclusive Option. At any time during the Access
Term, Millennium shall have the right to [ * ] that it [ * ] to [ * ]. In each
such [ * ], Millennium shall [ * ] of the [ * ] which it [ * ] to [ * ] of the [
* ].

      3.3 Target Antigen Availability. Within [ * ] following [ * ] of [ * ]
from Millennium regarding its [ * ] with respect to a particular [ * ],
ImmunoGen shall [ * ] Millennium [ * ] is available with respect to such [ * ].
An [ * ] shall be made available to Millennium with respect to such [ * ] in
accordance with the terms of [ * ] of this Agreement unless (a) ImmunoGen [ * ]
from Millennium or (b) ImmunoGen [ * ] that [ * ] with such [ * ] with a [ * ]
and [ * ] for an [ * ] of ImmunoGen [ * ] of the [ * ] from Millennium. [ * ]
with respect to [ * ] is [ * ] shall [ * ] to such [ * ] continue to have the [
* ] with such [ * ] of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       8
<PAGE>

      3.4 Option License. With respect to each [ * ] as to which ImmunoGen
notifies Millennium that an [ * ] is available in accordance with [ * ] of this
Agreement (each, a "[ * ]"), ImmunoGen hereby grants to Millennium (a) a [ * ],
with (i) an [ * ] and an (ii) [ * ], and (b) [ * ], during the term of the [ *
], to obtain an [ * ] in connection with the Millennium [ * ]. The [ * ] set
forth in [ * ] of this [ * ] shall include the right to [ * ] of Millennium, [ *
] of [ * ] of Millennium, and [ * ] with respect to [ * ] Millennium [ * ] with
the Millennium [ * ]. For purposes of clarity, the [ * ] set forth in this [ * ]
shall include the right to access [ * ] in accordance with [ * ] hereof for the
purpose of [ * ].

      3.5 Right to Supply. During the term of any [ * ], ImmunoGen [ * ] to [ *
] Millennium with its requirements of [ * ] for the purpose of [ * ] in
accordance with [ * ] of this Agreement. The terms of [ * ] of this Agreement
shall govern [ * ] of such [ * ]. Alternatively, during the term of any [ * ],
Millennium shall have the right, and ImmunoGen hereby grants to Millennium a
non-exclusive, worldwide, royalty-free license under the Licensed Technology, to
[ * ] of [ * ] for the purpose of conducting Preclinical Research in accordance
with [ * ] of this Agreement. For purposes of clarity, the [ * ] set forth in
this [ * ] shall include [ * ] to [ * ] in accordance with [ * ] hereof for the
purpose of [ * ] in accordance with this [ * ]. The license grant set forth in
this [ * ] shall include [ * ] to [ * ] to [ * ] and [ * ] who [ * ] on [ * ] of
Millennium.

      3.6 Use of Cytotoxic Compound, other ImmunoGen Materials and AB-Cytotoxic
Product. In connection with the licenses set forth in Section 3.4 and Section
3.5, Millennium hereby agrees that it (a) shall not use the Cytotoxic Compounds,
other ImmunoGen Materials and/or AB-Cytotoxic Products in any human subject, (b)
shall use the Cytotoxic Compounds, other ImmunoGen Materials and/or AB-Cytotoxic
Products in compliance with all applicable federal, state and local laws and
regulations, and (c) as a matter of contract between itself and ImmunoGen, shall
assume all liability for damages that may arise from the use, storage and
disposal of any Cytotoxic Compounds, other ImmunoGen Materials and/or
AB-Cytotoxic Products. [ * ] shall be [ * ] (pursuant to the [ * ] under terms [
* ] to [ * ].

      3.7 Term and Expiration of Exclusive Option. Each Exclusive Option shall
extend for a term of [ * ] from [ * ] by ImmunoGen that the [ * ] is [ * ] in
accordance with [ * ] of this Agreement, subject to renewal in accordance with
Section 3.9 of this Agreement. Upon the expiration of an Exclusive Option,
Millennium shall

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       9
<PAGE>

continue to have the right to work with such Target Antigen in accordance with
the license granted in Section 2.3 of this Agreement.

      3.8 Early Termination of Exclusive Option. With respect to any given
Exclusive Option, Millennium [ * ] by providing written notice to ImmunoGen.
Upon such election, Millennium shall continue to have [ * ] with such [ * ] in
accordance with the [ * ] of this Agreement. In the event of [ * ] of an
Exclusive Option, Millennium may [ * ] to obtain an Exclusive Option to such
Target Antigen until [ * ] have passed since [ * ] of the Exclusive Option for
such Target Antigen; provided, that, ImmunoGen agrees to consider, in good
faith, any requests made by Millennium prior to the expiration of such [ * ] to
re-elect to obtain an Exclusive Option to such Target Antigen.

      3.9 Renewal of Exclusive Options. Prior to the expiration of any Exclusive
Option, Millennium shall have [ * ] to extend the term of any Exclusive Option
by an additional [ * ] by providing written notification to ImmunoGen.

      3.10 [ * ]. [ * ] upon the [ * ].

4. EXCLUSIVE LICENSES

      4.1 Exercise of an Exclusive Option. At any time during the term of an
Exclusive Option, Millennium shall have the right to [ * ] with respect to the
particular Millennium [ * ] covered by the [ * ]. Upon such notification,
Millennium shall be granted an [ * ] with respect to such Millennium [ * ] in
accordance with [ * ] of this Agreement.

      4.2 Obtaining an Exclusive License without an Exclusive Option. At any
time during the Access Term, Millennium may elect to seek an [ * ] prior to
obtaining [ * ]. If, with respect to any particular [ * ], Millennium shall
desire, during the Access Term, to enter into an [ * ] without previously [ * ],
Millennium shall notify ImmunoGen in writing that it wishes to obtain an [ * ]
with respect to such [ * ] and shall include in the written notification
relating to such [ * ] of such [ * ].

      4.3 [ * ] for an Exclusive License. Within [ * ] following [ * ] regarding
[ * ] an [ * ] with respect to [ * ] that [ * ] shall [ * ] whether an [ * ]
with respect to [ * ]. The determination as to whether or not an [ * ] shall be
made available to Millennium shall be based on the same criteria as is set forth
in [ * ] of this Agreement. If ImmunoGen notifies Millennium that an [ * ] is
available for a particular [ * ], Millennium shall be granted an [ * ] with
respect to such [ * ] in accordance with [ * ] of this Agreement. If ImmunoGen
notifies Millennium that an [ * ] with respect

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       10
<PAGE>

to a particular [ * ] is not available, Millennium shall not be granted an [ * ]
to such [ * ], but shall continue to have the right to work with such [ * ] in
accordance with the license granted in [ * ] of this Agreement.

      4.4 [ * ] of Exclusive Licenses. There shall be [ * ] on the [ * ] of [ *
] which Millennium [ * ] from ImmunoGen.

      4.5 Exclusive License. With respect to each Millennium [ * ] for which
Millennium has obtained and exercised an [ * ] and with respect to each [ * ] as
to which ImmunoGen notifies Millennium that an [ * ] ImmunoGen hereby grants
Millennium (a) [ * ] for the purpose of [ * ] with (i) an [ * ] and (ii) an [ *
] the [ * ] for the purpose of [ * ] containing (i) [ * ] selected [ * ] and
(ii) an [ * ] and (c) [ * ] under the [ * ] containing (i) [ * ] and (ii) and [
* ] that [ * ]. The [ * ] set forth in [ * ] shall include the [ * ] who [ * ]
on behalf, and under the direction of [ * ] with respect to [ * ] that [ * ] In
the event of a sublicense, Millennium shall remain obligated to ensure payment
of all milestone and royalty obligations set forth in Section 6 of this
Agreement. For purposes of clarity, the Parties agree that development and/or
marketing partners of Millennium shall include [ * ] in the event that
Millennium's [ * ]. For purposes of clarity, the [ * ] set forth in this [ * ]
shall include the right to [ * ] in accordance with [ * ] hereof for the purpose
of conducting [ * ] and [ * ] that [ * ] with the [ * ].

      4.6 Right to [* ]. During the term of any [ * ], ImmunoGen [ * ] with its
requirements of [ * ] for the purpose of conducting [ * ] in accordance with [ *
] of this Agreement and, with respect to the first Millennium [ * ] for which
Millennium obtains an [ * ] for the purpose of [ * ] in accordance with [ * ] of
this Agreement. The terms of [ * ] of this Agreement shall govern the [ * ] of
such [ * ] (including, with respect to clinical [ * ] the [ * ] to enter into a
separate [ * ] detailing the terms of [ * ] of each such [ * ]. Alternatively,
during the term of any [ * ], Millennium shall have the right, and ImmunoGen
hereby grants to Millennium a non-exclusive, worldwide, royalty-free license
under the Licensed Technology, [ * ] of [ * ] for the purpose of [ * ] in
accordance with [ * ] of this Agreement and, with respect to the [ * ] for which
Millennium obtains an [ * ], for the purpose of [ * ] in accordance with [ * ]
of this Agreement. Under any given [ * ], Millennium shall be responsible for
its further clinical and for its commercial requirements of [ * ]. Accordingly,
ImmunoGen hereby grants to Millennium a non-exclusive, worldwide, royalty-free
license under the Licensed Technology, to [ * ] under any given [ * ]. For
purposes of clarity, the [ * ] set forth in this [ * ]

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       11
<PAGE>

shall include [ * ] in accordance with [ * ] hereof for the purpose of [ * ] in
accordance with this [ * ]. The [ * ] set forth in this [ * ] shall include the
[ * ] who [ * ] on [ * ] Millennium.

      4.7 License Fees. Millennium shall pay to ImmunoGen an [ * ] for each [ *
] obtained by Millennium. Such fee shall be payable within [ * ] after (a) the [
* ] in accordance with [ * ] of this Agreement or (b) the receipt by Millennium
of the notice from ImmunoGen that an [ * ] in accordance with [ * ] of this
Agreement.

      4.8 Milestones and Royalties. With respect to each [ * ] obtained by
Millennium, the terms of Article 6 shall apply.

      4.9 Term. Upon expiration of all royalty obligations with respect to an [
* ], such license shall become a fully-paid up [ * ].

      4.10 Diligence. Under each [ * ], Millennium shall exercise commercially
reasonable efforts and diligence in developing and commercializing an
AB-Cytotoxic Product in accordance with its business, legal, medical and
scientific judgment, and in undertaking investigations and actions required to
obtain appropriate regulatory approvals necessary to market an AB-Cytotoxic
Product, such reasonable efforts and diligence to be in accordance with the
efforts and resources Millennium would use for a compound owned by it, or to
which it has rights, which is of similar market potential at a similar stage in
development as the applicable AB-Cytotoxic Product, taking into account the
competitiveness of the marketplace, the proprietary position of the AB-Cytotoxic
Product, the relative potential safety and efficacy of the AB-Cytotoxic Product,
the regulatory requirements involved in its development, commercialization and
regulatory approval, the cost of goods and availability of capacity to
manufacture and supply the AB-Cytotoxic Product at commercial scale, the
profitability of the applicable AB-Cytotoxic Product, and other relevant factors
including, without limitation, technical, legal, medical or scientific factors.
In the event that Millennium materially breaches its obligation to use due
diligence as required under this Section 4.10 with respect to a particular [ *
], ImmunoGen shall notify Millennium in writing. Upon receipt of any such
notification, the Parties shall meet to discuss the nature of such material
breach and Millennium shall thereupon have [ * ] in which to cure such breach
or, if such breach is not curable within such [ * ], Millennium shall thereupon
have [ * ] in which to commence such cure and make diligent attempts to cure as
promptly as possible. If, at the end of such [ * ] such breach remains uncured
or, if such breach is not curable within such [ * ] Millennium shall not have
commenced and made diligent attempts to cure as promptly as possible, then, as
to the [ * ] for which Millennium has materially breached its obligation to use
due diligence as required under this Section 4.10, ImmunoGen shall have the
right, at its option, to (a) convert such [ * ] (i.e., the licenses granted
under Section 4.5 of this Agreement) from [ * ] to [ * ], subject to the
continuation of all of the other provisions of this Agreement, or (b) terminate
the [ * ].

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       12
<PAGE>

      4.11 Reports and Notices. With respect to each [ * ], commencing with the
first anniversary of the date on which Millennium obtains an [ * ], Millennium
(or its Affiliates or sublicensees permitted pursuant to this Agreement) shall
provide ImmunoGen with. brief written reports, no less frequently than annually
during the term of the Agreement, summarizing Millennium's material efforts to
develop and commercialize AB-Cytotoxic Product under such [ * ], identify the
drug approval applications with respect to any AB-Cytotoxic Product that
Millennium (or its Affiliates or sublicensees permitted pursuant to this
Agreement) have filed, sought or obtained in the prior twelve (12) month period,
and any such applications they reasonably expect to make, seek or attempt to
obtain in the following twelve (12) month period. In addition, Millennium (or
its Affiliates or sublicensees permitted pursuant to this Agreement) shall
provide ImmunoGen with prompt written notice of the occurrence of any event
giving rise to an obligation to make a milestone payment to ImmunoGen under
Section 6.1 of this Agreement, and shall provide ImmunoGen with prompt written
notice of the occurrence of the first bona fide commercial sale of an
AB-Cytotoxic Product.

      4.12 Adverse Event Reporting. Each Party agrees to report to the other
Party each "serious adverse experience" which constitutes an Adverse Event which
the other Party is required to report to the United States Food and Drug
Administration, or foreign equivalent thereof, in a timeframe consistent with
that necessary for the reporting Party to comply with its regulatory obligations
to the United States Food and Drug Administration, or foreign equivalent
thereof, to the extent that such disclosure does not violate any of such Party's
confidentiality obligations to Third Parties. Further, for informational
purposes, each Party agrees to voluntarily report to the other Party any
"serious adverse experience" and any repeated "unexpected adverse experience,"
which constitutes an Adverse Event which such Party is required to report to the
United States Food and Drug Administration, to the extent that such disclosure
does not violate any of such Party's confidentiality obligations to Third
Parties. In addition, either Party may report any such Adverse Events to Third
Parties; provided, that (i) such reporting is necessary under applicable laws or
customary ethical obligations in such Party's industry, (ii) the disclosing
Party provides prior written notice to the other Party of its intention to
report such Adverse Event, and (iii) unless otherwise mutually agreed upon by
the Parties, the disclosing Party does not reveal the identity of the
AB-Cytotoxic Product or the identity of the original reporting Party. After
Millennium obtains its first [ * ], the Parties shall work together to develop a
system for the mutual reporting of Adverse Events.

      4.13 Confidential Information. All reports, notices and information
provided by one Party to the other Party under Section 4.11 or 4.12 of this
Agreement shall be considered Confidential Information of the Party providing
such report, notice or information, subject to the terms of Section 8 of this
Agreement.

5. SUPPLY

      5.1 General Obligations. During the Access Term, ImmunoGen [ * ] to [ * ]
Millennium with its [ * ] of [ * ] [ * ] containing Millennium [ * ] for the
purpose of conducting Preclinical Research in accordance with Section 2 of this
Agreement. During the term of any given Exclusive Option, ImmunoGen shall use

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       13
<PAGE>

commercially reasonable efforts to supply Millennium with its requirements of [
* ] containing [ * ] with the [ * ] which is the subject of the [ * ], and
containing [ * ], for the purpose of conducting [ * ] in accordance with [ * ]
of this Agreement. During the term of any given [ * ], ImmunoGen shall supply
Millennium with its [ * ] of [ * ] containing [ * ] which is the subject of the
[ * ], and containing [ * ], for the purpose of conducting [ * ] in accordance
with [ * ] of this Agreement and, with respect to the first Millennium [ * ] for
which Millennium obtains an [ * ], for the purpose of [ * ] in accordance with [
* ] of this Agreement. For purposes of the foregoing obligations, Millennium's
requirements shall include those of its Affiliates and sublicensees permitted
pursuant to this Agreement. With respect to [ * ], the foregoing obligations of
ImmunoGen shall be contingent on ImmunoGen's receipt of the [ * ] from
Millennium.

      5.2 [ * ]. All [ * ] supplied by ImmunoGen to Millennium for the purpose
of [ * ] under this Agreement shall be supplied in accordance with [ * ] through
[ * ] of this Agreement. Anything to the contrary notwithstanding, with respect
to any given [ * ], ImmunoGen and Millennium shall enter into a separate supply
agreement detailing the terms of supply for any Cytotoxic Compound or
AB-Cytotoxic Product that ImmunoGen is obligated to supply to Millennium for the
purpose of conducting clinical trials, which supply agreement (a) shall include,
without limitation, provisions for the items set forth on [ * ] and (b) may,
upon mutual agreement of the Parties, include provisions for [ * ] clinical
requirements of Cytotoxic Compound and AB-Cytotoxic Product (i.e., [ * ] in
addition to the [ * ] obligations of ImmunoGen set forth in [ * ] of this
Agreement) and for Millennium's commercial requirements of [ * ].

      5.3 Forecasts, Orders and Delivery. Within [ * ] of the Effective Date (or
such mutually agreed upon later date), the Parties shall agree on a [ * ] and on
[ * ] for the supply of Cytotoxic Compound and AB-Cytotoxic Product for the
purpose of conducting Preclinical Research under the terms of this Agreement.
Notwithstanding any agreed [ * ], with respect to the First Exclusive Option,
Millennium shall have the right, at any time, to supply ImmunoGen with (a) up to
[ * ] of the Millennium [ * ] which is [ * ] and (b) [ * ] of each of up to [ *
] for the production by ImmunoGen of [ * ] containing the Millennium [ * ]. With
respect to each of the [ * ] and each of the [ * ], Millennium shall notify
ImmunoGen in writing no later than [ * ] in advance of a [ * ] specifying, in
each case, the [ * ], the [ * ], the [ * ] selected by Millennium from the [ * ]
of ImmunoGen, and the [ * ] is expected to be [ * ] ImmunoGen. [ * ] after
ImmunoGen's receipt of a [ * ], ImmunoGen shall [ * ] of the [ * ] with the [ *
] selected by Millennium, with the goal of [ * ] of such [ * ]. Except as
otherwise agreed to by the

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       14
<PAGE>

Parties, all deliveries of [ * ] shall be [ * ] the facility used by ImmunoGen
for [ * ] of [ * ].

      5.4 Standards for Supply of Preclinical Grade Material. Unless otherwise
mutually agreed to by the Parties, (a) all Cytotoxic Compound supplied to
Millennium under the terms of this Agreement for purposes of Preclinical
Research shall meet the specifications for such Cytotoxic Compound as are
mutually agreed to by the Parties, (b) all AB-Cytotoxic Product supplied to
Millennium under the terms of this Agreement for purposes of Preclinical
Research shall meet the specifications for such AB-Cytotoxic Product as are set
forth on [ * ] to this Agreement, and (c) if requested by Millennium, all
AB-Cytotoxic Product supplied to Millennium under the terms of this Agreement
for purposes of Preclinical Research shall be produced in accordance with
current Good Laboratory Practices ("cGLPs"), including, without limitation, the
additional specifications identified in [ * ] as necessary for compliance with
cGLPs. At the time of delivery of any Cytotoxic Compound or AB-Cytotoxic Product
to Millennium (or its designee) for purposes of Preclinical Research, such
Cytotoxic Compound or AB-Cytotoxic Product shall have been produced, conjugated,
manufactured, stored, packaged, labeled, shipped and/or delivered in compliance
with all applicable laws, regulations, rules and requirements, including,
without limitation, in the case of Cytotoxic Compound or AB-Cytotoxic Product
requested by Millennium to comply with cGLPs, cGLPs. With respect to each
shipment to Millennium involving supply for the purposes of Preclinical
Research, ImmunoGen shall provide Millennium with a Certificate of Analysis in a
form agreed to by the Parties indicating that the Cytotoxic Compound or
AB-Cytotoxic Product meets the specifications called for by this Section 5.4 and
shall provide Millennium with a Material Safety Data Sheet (MSDS).

      5.5 Supply Price. Cytotoxic Compound supplied to Millennium for the
purpose of [ * ] shall be supplied at [ * ] and [ * ] supplied to Millennium for
purposes [ * ] shall be supplied at [ * ]. With respect to any given [ * ], each
separate supply agreement entered into in accordance with Section 5.2 of this
Agreement for Millennium's clinical and/or commercial requirements of Cytotoxic
Compound and/or AB-Cytotoxic Product shall provide for a supply price [ * ].
ImmunoGen acknowledges that, as of the Effective Date, (a) its [ * ] for [ * ]
is equal to, on average, [ * ], (b) the conjugation of [ * ] is equal to, on
average, [ * ], and (c) its [ * ] for the [ * ] for purposes of [ * ] is equal
to, on average, [ * ]. Further, ImmunoGen anticipates that, commencing [ * ],
its Direct Cost of Cytotoxic Compound for [ * ] will be equal to, on average, [
* ]. ImmunoGen agrees to use commercially reasonable efforts to efficiently
produce all Cytotoxic Compound and AB-Cytotoxic Product supplied under this
Agreement for the purpose of [ * ] and acknowledges that, as of the Effective
Date, its [ * ] during the [ * ].

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       15
<PAGE>

      5.6 Invoices and Payment. With respect to all [ * ] supplied by ImmunoGen
to Millennium for the purpose of [ * ] under this Agreement, ImmunoGen shall
invoice Millennium for [ * ] of the [ * ] upon receipt from Millennium of an
order or, with respect to the [ * ] under the [ * ], a notice made in accordance
with Section 5.3 of this Agreement, and shall invoice Millennium for the balance
of the [ * ] at the [ * ] of the [ * ] to Millennium. Millennium shall pay all
such invoices within [ * ] of receipt unless subject to a good faith dispute, in
which case, (a) Millennium shall pay any undisputed amounts within such [ * ]
and (b) the Parties shall commence discussions to resolve such dispute as soon
as practicable. If the Parties are unable to resolve such dispute within [ * ],
then, unless the Parties mutually agree to an extension of such time period,
either Party shall have the right to refer the matter to arbitration in
accordance with Section 12.7 (b), it being understood that if the arbitrators
determine that such disputed payment is rightfully payable to ImmunoGen,
Millennium shall reimburse the reasonable costs and expenses incurred by
ImmunoGen in connection with such arbitration.

      5.7 Failure to Meet Specifications. In the event that any [ * ] supplied
to Millennium for the purpose of [ * ] under the terms of this Agreement shall
fail to meet the specifications for such [ * ] or [ * ], or ImmunoGen shall
otherwise fail to comply with the provisions of [ * ] of this Agreement,
ImmunoGen shall, at [ * ], it being understood that, with respect to any [ * ],
the obligation of ImmunoGen to [ * ] such [ * ] shall be contingent on
ImmunoGen's [ * ]. Further, in the event that such failure involves the [ * ]
and results in the [ * ], Millennium shall be entitled to a [ * ] from ImmunoGen
[ * ] for such [ * ].

      5.8 Use of Millennium Antibodies and Control Antibodies. With respect to
all [ * ] supplied under this Agreement, ImmunoGen hereby agrees to [ * ] solely
to [ * ] on behalf of Millennium and further agrees not to [ * ] any [ * ] or [
* ] (or any [ * ] or [ * ) ] to any [ * ] other than a [ * ], who agrees to be
bound by the terms of [ * ], in order to [ * ] to Millennium under this
Agreement. Other than the right to use a [ * ] in the [ * ] to produce [ * ] on
behalf of Millennium, no [ * ] to any [ * ] (or any [ * ] containing any [ * ]
is herein granted or implied as a result of the [ * ] of such [ * ] to
ImmunoGen.

      5.9 Transfer of Data for Regulatory Purposes. ImmunoGen shall furnish to
Millennium such data, information and materials concerning the production of
Cytotoxic Compound or AB-Cytotoxic Product under this Agreement as shall be
reasonably requested by Millennium in connection with any required regulatory
approvals for AB-Cytotoxic Products which are the subject of an [ * ] obtained
by Millennium.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       16
<PAGE>

      5.10 Millennium Inspections. ImmunoGen shall make the facilities used by
it to produce Cytotoxic Compound or AB-Cytotoxic Product supplied under this
Agreement, including records and samples relating to such Cytotoxic Compound or
AB-Cytotoxic Product, available for inspection by employees and representatives
of Millennium and representatives of regulatory agencies. Such inspections shall
be available to Millennium during regular business hours, upon reasonable notice
from Millennium, solely to verify compliance with applicable laws, regulations,
rules and requirements, including, without limitation, cGLPs. Millennium agrees
to hold in strict confidence all information obtained from any such inspection,
except to the extent necessary for Millennium to reveal such information in
order to enforce its rights under this Agreement or if disclosure is required by
law, regulation or judicial order. Millennium shall bear its own costs and
expenses associated with any such inspections.

      5.11 Governmental Inspections. ImmunoGen shall notify Millennium within [
* ] if the FDA or any other governmental or regulatory authority visits a
facility in which Cytotoxic Compound or AB-Cytotoxic Product is produced on
behalf of Millennium under this Agreement or makes written or oral inquiries
relating to a Cytotoxic Compound or an AB-Cytotoxic Product produced on behalf
of Millennium under this Agreement. ImmunoGen shall, immediately upon receipt of
any communication from any governmental or regulatory authority relating to any
such Cytotoxic Compound or AB-Cytotoxic Product, forward a copy or description
of the same to Millennium and respond to all inquiries by Millennium relating
thereto. Millennium shall have sole responsibility for all communications with
any governmental or regulatory authority relating to the AB-Cytotoxic Products.
If ImmunoGen is advised by its legal counsel that it must communicate with any
such governmental or regulatory authority in respect of a Cytotoxic Compound or
an AB-Cytotoxic Product, then it shall so advise Millennium immediately, and,
unless prohibited by applicable law or regulation, provide Millennium in advance
with a copy of any proposed written communication and comply with any and all
reasonable direction of Millennium concerning any meeting or written or oral
communication with any governmental or regulatory authority relating to the
Cytotoxic Compound or AB-Cytotoxic Product.

      5.12 Audits of Direct Cost. ImmunoGen shall keep complete and accurate
records of its [ * ] and [ * ] supplied under this Agreement in sufficient
detail to allow such [ * ] to be determined accurately. Millennium shall have
the right, during the term of this Agreement and for a period of [ * ] after the
termination of this Agreement, [ * ] reasonably acceptable to ImmunoGen to [ * ]
of ImmunoGen to verify its statements of [ * ] and [ * ]. ImmunoGen shall each
make its [ * ] available for inspection by such independent certified public
accountant during regular business hours at such place or places where such [ *
] are customarily kept, upon reasonable notice from Millennium, solely to verify
the accuracy of its statements of [ * ]. Such inspection right shall not be
exercised more than [ * ] during any [ * ] period. Millennium agrees to hold in
strict confidence all information concerning ImmunoGen's [ * ], and all
information learned in the course of any audit or inspection, except to the
extent necessary for Millennium to reveal such information in order to enforce
its rights under this Agreement or if disclosure is required by law, regulation
or judicial order. The results of each

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       17
<PAGE>

inspection, if any, shall be binding on both Parties. Millennium shall pay for
such inspections, except that, in the event an inspection [ * ] to Millennium of
[ * ], ImmunoGen shall [ * ].

      5.13 Purchase of Dedicated Equipment. If, during the Access Term,
ImmunoGen determines in good faith that it is necessary or advisable to purchase
dedicated equipment or instruments in order to perform any of its obligations to
manufacture Cytotoxic Compounds and/or AB Cytotoxic Products under this
Agreement for the purpose of conducting Preclinical Research, then ImmunoGen
shall provide Millennium with written notice of such determination, along with
the estimated price for such purchase and quality parameters for the equipment
or instruments, for Millennium's written approval of such price and features.
Subject to the foregoing, promptly after the consummation of such purchase on
behalf of Millennium, ImmunoGen shall provide Millennium with a copy of the
invoice or invoices reflecting such purchase, and Millennium shall reimburse
ImmunoGen for the purchase of all such approved equipment hereunder [ * ] of its
receipt of such invoices from ImmunoGen. All such equipment shall be owned by
Millennium, shall [ * ] so long as ImmunoGen has possession thereof, and shall
be used by ImmunoGen solely for the benefit of Millennium. The Parties hereby
agree that no costs which are incurred by ImmunoGen and reimbursed by Millennium
under this Section 5.13 shall be included within the calculation of any [ * ]
under this Agreement. Upon any termination of this Agreement, all such equipment
shall be transferred to Millennium, provided, that any reimbursement due from
Millennium for such equipment has been fully paid to ImmunoGen.

      5.14 Transfer of ImmunoGen Materials and Manufacturing Technology. At such
time as Millennium shall request in writing, ImmunoGen shall transfer to
Millennium such ImmunoGen [ * ] by it and provide such [ * ] as is reasonably
necessary for Millennium to [ * ] and to [ * ] and [ * ] as contemplated under
this Agreement. In addition, at such time as Millennium shall request, ImmunoGen
shall disclose to Millennium [ * ], if any, and [ * ], if any.

      5.15 Manufacturing Committee. Promptly after the execution of this
Agreement, the Parties shall form a manufacturing committee consisting of two
(2) designees from each Party (the "Manufacturing Committee") for the purpose of
(a) overseeing the supply of Cytotoxic Compound and AB-Cytotoxic Product under
this Agreement and the separate supply agreements entered into pursuant to
Section 5.2 of this Agreement, (b) overseeing the establishment of systems for
forecasting, ordering and delivering Cytotoxic Compound and AB-Cytotoxic
Products under this Agreement and the separate supply agreements entered into
pursuant to Section 5.2 of this Agreement, (c) overseeing the transfer of the [
* ] to Millennium for the purpose of Millennium's exploiting its [ * ] under
this Agreement, (d) overseeing the transfer of [ * ] by Millennium to ImmunoGen
for the purpose of ImmunoGen's [ * ] in accordance with the terms of this
Agreement, (e) determining the need to purchase dedicated equipment on behalf of
Millennium for the purpose of supply under this Agreement and the separate
supply agreements entered into pursuant to Section 5.2 of this

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       18
<PAGE>

Agreement, (f) discussing the expertise, capacity and selection of existing and
prospective contract manufacturers, and (g) such other matters as the Parties
shall mutually agree to delegate to the Manufacturing Committee. The
Manufacturing Committee shall meet at such times and places as are mutually
agreed to by the Parties. The Manufacturing Committee shall act as a facilitator
of the Parties with the understanding that all required approvals and consents
for actions under this Agreement, and the separate supply agreements entered
into pursuant to Section 5.2 of this Agreement, shall require the approval or
consent of the Parties.

6. COMMERCIALIZATION MILESTONES AND ROYALTIES.

      6.1 Milestones for AB-Cytotoxic Products. With respect to each [ * ]
obtained by Millennium, within [ * ], Millennium shall pay to ImmunoGen the
following milestones for each [ * ] developed under such [ * ]:

-----------------------------
$ [ * ]         [ * ]
-----------------------------
$ [ * ]         [ * ]
-----------------------------
$ [ * ]         [ * ]
-----------------------------
$ [ * ]         [ * ]
-----------------------------
$ [ * ]         [ * ]
-----------------------------

Millennium shall promptly provide ImmunoGen with written notice of the
achievement of each milestone referenced in this Section 6.1. Notwithstanding
the foregoing, with respect to each [ * ] developed under an [ * ], only [ * ]
will be due regardless of the number of indications pursued for such [ * ] and
regardless of the number of countries in which such milestone is achieved.
Further, notwithstanding the foregoing, payment for a milestone will not be due
with respect to an [ * ] developed under an [ * ] if such product represents a
change in form, formulation or dosage or if such product is a [ * ] for an [ * ]
developed under the [ * ] and for which such milestone has been previously paid.

      6.2 Royalty on AB-Cytotoxic Products.

            (a) With respect to each [ * ] which is the subject of an [ * ]
granted by ImmunoGen to Millennium, Millennium shall pay to ImmunoGen on a
country-by-country basis, a royalty on [ * ] of such [ * ] as follows:

[ * ]      [ * ] Royalty Rate
-----------------------------

[ * ]      [ * ]
[ * ]      [ * ]
[ * ]      [ * ]

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       19
<PAGE>

The [ * ] set forth above shall only apply to that portion of the [ * ] that [ *
]. For example, where the worldwide [ * ] of an [ * ] in a [ * ] for such [ * ]
shall be equal to [ * ] of the [ * ] of the next [ * ] of that [ * ].

            (b) Royalty Term. Royalties due pursuant to this Section 6.2 shall
be payable on a country-by-country and product-by-product basis until the longer
of (a) the expiration of the last to expire of the patents within the ImmunoGen
Patent Rights covering the AB-Cytotoxic Product in such country and (b) [ * ]
from the first bona fide commercial sale of an AB-Cytotoxic Product in such
country.

            (c) Royalty Payable Only Once. The obligation to pay royalties shall
be imposed only once with respect to the same unit of AB-Cytotoxic Product sold
by Millennium or its Affiliates or sublicensees.

            (d) Overdue Royalties. Royalties not paid within the time period set
forth in this Section 6 shall bear interest at a rate of one percent (1%) per
month from the due date until paid in full.

      6.3 [ * ] for Third Party Patents.

            (a) Notification. If either Party becomes aware of a [ * ] during
the term of this Agreement, or any [ * ] that would constitute a [ * ], such
Party shall promptly notify the other Party and, except to the extent that such
Party is prohibited under a duty of confidentiality from disclosing such
information, provide a reasonably detailed summary of its knowledge regarding
such [ * ] (including, by way of example and without limitation, the [ * ] or [
* ], the subject matter of the [ * ], and any available information about terms
offered or asked with respect to [ * ] under such [ * ]. ImmunoGen shall have
the first right to negotiate with any [ * ] for a [ * ] under any such [ * ];
and provided, however, that ImmunoGen shall not be obligated to negotiate for or
obtain such a [ * ]; and provided, further, that if ImmunoGen elects not to
negotiate for such a [ * ] it shall promptly notify Millennium of such election,
and Millennium shall thereafter be free to negotiate such a [ * ] on its own
behalf.

            (b) ImmunoGen Responsibility. If ImmunoGen obtains a [ * ], such [ *
] shall be included in [ * ] and be [ * ] to Millennium under the terms and
conditions of this Agreement.

            (c) [ * ]. For [ * ] of an [ * ] for which a royalty is due under
the terms of a license to a [ * ], and where the license is obtained by
Millennium, Millennium shall have the right [ * ] by Millennium to ImmunoGen
under [ * ] of this Agreement for such [ * ] up to [ * ] of the payments made by
Millennium in respect of its license to such [ * ] for such AB-Cytotoxic
Product; provided, however, that the [ * ] otherwise [ * ] to

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       20
<PAGE>

ImmunoGen under [ * ] of this Agreement shall not be reduced, as a result of
such deduction, by more than [ * ]. Any deduction hereunder, or portion thereof,
that is rendered not usable pursuant to such deduction limitations may be [ * ]
for use [ * ].

      6.4 Reports. Millennium shall deliver to ImmunoGen within [ * ] after the
last day of each calendar quarter in which [ * ] are sold [ * ] ImmunoGen for
such [ * ]. For purposes of determining when a [ * ] under this Agreement, the
sale shall be deemed to occur [ * ].

      6.5 Payments. All royalties due to ImmunoGen under this Agreement shall be
paid within [ * ] after the [ * ] in which they [ * ] and shall be paid in
United States Dollars by check or wire transfer in immediately available funds
to the account designated by ImmunoGen by written notice to Millennium from time
to time during the term of this Agreement. If any currency conversion shall be
required in connection with the calculation of the royalties payable hereunder,
such conversion shall be made using the selling exchange rate for conversion of
the foreign currency into United States Dollars quoted for current transactions
as reported in the East Coast Edition of The Wall Street Journal for the last
business day of the calendar quarter to which such payment pertains.

      6.6 Taxes. All royalty amounts required to be paid to ImmunoGen pursuant
to this Agreement shall be made free and clear of any taxes, duties, levies,
fees or charges, except that a deduction may be made for any withholding taxes
(other than taxes imposed on or measured by net income) or similar government
charge imposed by a jurisdiction other than the United States. Millennium shall
provide ImmunoGen a certificate evidencing payment of any such withholding
taxes.

      6.7 Records and Inspection. Millennium shall keep, and cause its
Affiliates and sublicensees to keep, complete, true and accurate books of
account and records for the purpose of determining the royalty amounts payable
to ImmunoGen under this Agreement. Such books and records shall be kept at the
principal place of business of Millennium or its Affiliates or sublicensees, as
the case may be, for at least [ * ] following the end of the calendar quarter to
which they pertain. Such records of Millennium or its Affiliates shall be open
for inspection during such three-year period by an independent certified public
accountant selected by ImmunoGen and reasonably acceptable to Millennium for the
purpose of verifying the royalty statements. Millennium shall require each of
its sublicensees to maintain similar books and records and to open such records
for inspection during the same [ * ] by an independent certified public account
selected by Millennium and reasonably satisfactory to ImmunoGen for the purpose
of verifying the royalty statements. All such inspections shall be made no more
than [ * ] each calendar year at reasonable times, and during regular business
hours, mutually agreed by ImmunoGen and Millennium. With respect to each
inspection, the independent certified public account shall be obliged to execute
a reasonable confidentiality agreement prior to commencing any such inspection.
Inspections conducted under this Section 6.7 shall be [ * ] of ImmunoGen unless
a variation

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       21
<PAGE>

or error producing an increase exceeding [ * ] of the amount stated for any
period is established in the course of any such inspection, whereupon all costs
relating to the audit of such period will be paid by Millennium.

7. INTELLECTUAL PROPERTY

      7.1 Ownership of Intellectual Property. ImmunoGen shall own all right,
title and interest in and to all Cytotoxic Compounds, ImmunoGen Materials,
Licensed Technology and, as between the Parties, Improvements made by ImmunoGen
and its Affiliates and sublicensees (other than Millennium). Millennium shall
own all right, title and interest in and to all Millennium Inventions,
Millennium Know-How, Millennium Materials, Millennium Patent Rights and, as
between the Parties, Improvements made by Millennium and its Affiliates and
sublicensees permitted pursuant to this Agreement. ImmunoGen and Millennium
shall jointly own all Improvements jointly made by ImmunoGen and Millennium.

      7.2 Licenses to Improvements.

            (a) All Improvements Controlled by ImmunoGen shall be included in
the Licensed Technology licensed to Millennium under the terms of this
Agreement.

            (b) Subject to [ * ] of this Agreement, [ * ] hereby grants to [ * ]
a [ * ], with the [ * ] to all [ * ]. In connection therewith, prior to the [ *
] of [ * ] of [ * ] shall cause [ * ] and shall [ * ] who [ * ].

            (c) ImmunoGen's right to license its [ * ] made jointly by ImmunoGen
and Millennium and ImmunoGen's [ * ] of this Agreement shall be limited such
that ImmunoGen may [ * ] to a [ * ] only if ImmunoGen is [ * ].

      7.3 Prosecution and Maintenance of Patents.

            (a) Rights of ImmunoGen. ImmunoGen shall have the exclusive right
and option, at its own expense, to file and prosecute any patent applications
and maintain any patents covering ImmunoGen Know-How, Improvements made solely
by ImmunoGen and its Affiliates, and Improvements made jointly by ImmunoGen and
its Affiliates with sublicensees (other than Millennium), provided that in the
event that ImmunoGen declines the option to file and prosecute any such patent
application or maintain any such patent, it shall give Millennium prompt notice
to this effect and thereafter Millennium may, at its own expense and in the name
of ImmunoGen, file and prosecute such patent applications and maintain such
patents.

            (b) Rights of Millennium. Millennium shall have the exclusive right
and option, at its own expense, to file and prosecute any patent applications
and maintain any patents covering

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       22
<PAGE>

Millennium Inventions or Improvements made solely by Millennium and its
Affiliates and sublicensees (permitted pursuant to this Agreement).

            (c) Joint Improvements. ImmunoGen shall have the exclusive right and
option, at its own expense and in the names of both Parties, to file and
prosecute any patent applications and maintain any patents covering Improvements
made jointly by ImmunoGen and Millennium, provided that in the event that
ImmunoGen declines the option to file and prosecute any such patent application
or maintain any such patent, it shall give Millennium prompt notice to this
effect and thereafter Millennium may, at its own expense and in the name of both
Parties, file and prosecute such patent applications and maintain such patents.

            (d) Cooperation. ImmunoGen and Millennium shall each cooperate with
the other with respect to the preparation, filing, prosecution, maintenance and
extension of patent applications and patents pursuant to this Section 7.3,
including, without limitation, the execution of all such documents and
instruments and the performance of such acts as may be reasonably necessary in
order to permit Millennium to continue any preparation, filing, prosecution,
maintenance or extension of patent applications and patents that ImmunoGen has
elected not to pursue as provided for in this Section 7.3.

      7.4 Infringement.

            (a) General. In the event that either Party becomes aware of any
infringement or misappropriation of any Licensed Technology or Improvement by a
Third Party, such Party shall promptly notify the other Party.

            (b) Rights of ImmunoGen. ImmunoGen shall have the exclusive right,
at its own expense, to bring an enforcement proceeding with respect to any
infringement or misappropriation involving Cytotoxic Compounds, ImmunoGen
Materials, Licensed Technology, Improvements made by ImmunoGen and its
Affiliates and sublicensees (other than Millennium), and Improvements made
jointly by ImmunoGen and Millennium. ImmunoGen shall keep Millennium reasonably
informed of the progress of such enforcement proceeding and shall give due
consideration to the suggestions and comments of Millennium. Any recovery
received by ImmunoGen as a result of any such enforcement proceeding shall be
used first to reimburse ImmunoGen for all out-of-pocket expenses, including
reasonable attorneys fees, incurred in connection with such enforcement
proceeding. To the extent that the remaining amount of the recovery, if any, is
in respect of [ * ], ImmunoGen and Millennium shall [ * ]. To the extent that
the remaining amount of the recovery, if any, is in respect of [ * ], with [ * ]
going to ImmunoGen and [ * ] going to Millennium. If ImmunoGen notifies
Millennium that it does not desire to pursue an enforcement action with respect
to a substantial and continuing infringement or misappropriation involving
Cytotoxic Compounds, ImmunoGen Materials, Licensed Technology, Improvements made
by ImmunoGen and its Affiliates and sublicensees (other than Millennium), or
Improvements made jointly by ImmunoGen and Millennium, Millennium may, at its
expense, bring such an enforcement action. Millennium shall

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       23
<PAGE>

keep ImmunoGen reasonably informed of the progress of such enforcement
proceeding and shall give due consideration to the suggestions and comments of
ImmunoGen. Any recovery received by Millennium as a result of any such
enforcement proceeding [ * ].

            (c) Rights of Millennium. Millennium shall have the exclusive right,
at its own expense, to bring an enforcement proceeding with respect to any
infringement or misappropriation involving any Millennium Inventions, Millennium
Know-How, Millennium Materials, Millennium Patent Rights, and Improvements made
by Millennium and its Affiliates and sublicensees (permitted pursuant to this
Agreement).

      7.5 Claimed Infringement. In the event that a Third Party at any time
provides written notice of a claim to, or brings an action, suit or proceeding
against, either Party (or any of their respective Affiliates or sublicensees
permitted pursuant to this Agreement), claiming infringement of its patent
rights or unauthorized use or misappropriation of its know-how, based upon an
assertion or claim arising out of the practice of the Licensed Technology or
Improvement, such Party shall promptly notify the other Party of the claim or
the commencement of such action, suit or proceeding, enclosing a copy of the
claim and all papers served. Each Party agrees to make available to the other
Party its advice and counsel regarding the technical merits of any such claim at
no cost to the other Party and to offer reasonable non-monetary assistance to
the other Party at no cost to the other Party. With respect to Improvements
which are jointly owned by ImmunoGen and Millennium, neither Party shall settle
any claims or suits involving rights of the other Party without the prior
written consent of the other Party.

8. CONFIDENTIALITY

      8.1 Confidentiality. Except as contemplated by this Agreement, each Party
shall hold in confidence and shall not publish or otherwise disclose and shall
not use for any purpose any Confidential Information of the other Party
disclosed to it pursuant to the terms of this Agreement until the [ * ]
anniversary of the date of disclosure of such Confidential Information.

      8.2 Permitted Disclosure. Notwithstanding Section 8.1 of this Agreement,
each Party may disclose the other Party's Confidential Information to the extent
such disclosure is required by applicable law, regulation or court order;
provided, that if a Party is required to make any such disclosure of the other
Party's Confidential Information, it will give reasonable advance notice to the
other Party of such disclosure requirement and will use efforts consistent with
prudent business judgment to secure confidential treatment of such information
prior to its disclosure, whether through protective orders or confidentiality
agreements or otherwise.

      8.3 Public Disclosure. Except as otherwise required by law, neither Party
shall issue a press release or make any other public disclosure of the terms of
this Agreement without the prior approval of such press release or public
disclosure by the other Party. Each Party shall submit any such press release or
public disclosure to the other Party, and the receiving Party shall have [ * ]
from receipt to review and approve any such press release or public disclosure,
which approval shall not be unreasonably withheld. If the receiving Party does
not respond to the other

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       24
<PAGE>

Party within such [ * ] period, the press release or public disclosure shall be
deemed approved. In addition, if a public disclosure is required by law,
including without limitation in a filing with the Securities and Exchange
Commission, the disclosing Party shall provide copies of the disclosure
reasonably in advance of such filing or other disclosure for the non-disclosing
Party's prior review and comment. The first approval of the contents of a press
release or public disclosure shall constitute permission to use such contents
subsequently without submission of the a press release or public disclosure to
the other Party for approval.

      8.4 Confidential Terms. Except as expressly provided herein, each Party
agrees not to disclose any terms of this Agreement to any Third Party without
the consent of the other Party; provided, however, that disclosures may be made
on a strict need-to-know basis (a) to a Party's accountants, attorneys and other
professional advisors and its actual or prospective investors and (b) with
respect to Millennium, to (i) [ * ] or (ii) [ * ] which [ * ] subject [ * ],
subject [ * ] that would [ * ] to [ * ]. In the case of the foregoing clause
(ii), [ * ] (A) Millennium shall provide ImmunoGen with [ * ] and (B) ImmunoGen
shall have the right, [ * ]. In the event that ImmunoGen fails to respond to
Millennium within such [ * ], Millennium shall have the right to proceed [ * ].
In any case, each party receiving a disclosure under this Section 8.4 shall have
executed a confidentiality agreement with, or be otherwise bound by an
obligation of confidentiality to, the disclosing Party.

9. INDEMNIFICATION

      9.1 Millennium. Millennium shall indemnify and hold harmless ImmunoGen and
its directors, officers, employees and agents (each an "ImmunoGen Indemnitee"),
from and against all losses, liabilities, damages and expenses, including
reasonable attorneys' fees (collectively, "Liabilities"), resulting from any
claims, demands, actions or other proceedings brought by any Third Party
relating to (a) the material breach of any representation, warranty or covenant
by Millennium under this Agreement, (b) personal injury or property damage
arising from the use by Millennium (or any of its Affiliates or sublicensees
permitted pursuant to this Agreement) of any Cytotoxic Compound or AB-Cytotoxic
Product for Preclinical Research, or (c) personal injury arising from the
development, use, manufacture, importation, distribution, offering for sale or
sale of any AB-Cytotoxic Product; provided, however, that Millennium shall not
be obligated to indemnify or hold harmless an ImmunoGen Indemnitee for such
Liabilities to the extent that such Liabilities arise from (x) the gross
negligence or willful misconduct of an ImmunoGen Indemnitee or (y) the failure
of any Cytotoxic Compound or AB-Cytotoxic Product supplied by ImmunoGen to meet
the requirements of Section 5.4 of this Agreement or any separate supply
agreement entered into pursuant to Section 5.2 of this Agreement. In the event
of any claim, demand, action or other proceeding brought against an ImmunoGen
Indemnitee by a Third Party, ImmunoGen shall promptly notify Millennium in
writing of the claim, demand, action or other proceeding, and Millennium shall
manage and control, at its sole expense, the defense of the claim, demand,
action or

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       25
<PAGE>

other proceeding and its settlement, keeping ImmunoGen reasonably apprised of
the status of the defense and/or settlement. The ImmunoGen Indemnified Parties
shall cooperate with Millennium and may, at their option and expense, be
represented in any such claim, demand, action or proceeding. Millennium shall
not be liable for any litigation costs or expenses incurred by the ImmunoGen
Indemnified Parties without Millennium's prior written consent.

      9.2 ImmunoGen. ImmunoGen shall indemnify and hold harmless Millennium, and
its directors, officers, employees and agents (each a "Millennium Indemnitee"),
from and against all Liabilities resulting from any claims, demands, actions or
other proceedings brought by any Third Party relating to (a) the material breach
of any representation, warranty or covenant by ImmunoGen under this Agreement or
(b) the failure of any Cytotoxic Compound or AB-Cytotoxic Product supplied by
ImmunoGen to meet the requirements of Section 5.4 of this Agreement or any
separate supply agreement entered into pursuant to Section 5.2 of this
Agreement; provided, however, that ImmunoGen shall not be obligated to indemnify
or hold harmless a Millennium Indemnity for such Liabilities to the extent that
such Liabilities arise from the gross negligence or willful misconduct of a
Millennium Indemnitee. In the event of any claim, demand, action or other
proceeding brought against a Millennium Indemnitee by a Third Party, Millennium
shall promptly notify ImmunoGen in writing of the claim, demand, action or other
proceeding, and ImmunoGen shall manage and control, at its sole expense, the
defense of the claim, demand, action or other proceeding and its settlement,
keeping Millennium reasonably apprised of the status of the defense and/or
settlement. The Millennium Indemnified Parties shall cooperate with ImmunoGen
and may, at their option and expense, be represented in any such claim, demand,
action or proceeding. ImmunoGen shall not be liable for any litigation costs or
expenses incurred by the Millennium Indemnified Parties without ImmunoGen's
prior written consent.

      9.3 Insurance. Each Party shall maintain insurance, including product
liability insurance, with respect to its activities under this Agreement. Such
insurance shall be in such amounts and subject to such deductibles as are
prevailing in the industry from time to time, provided that, each Party shall
maintain a minimum of an aggregate of [ * ] in general comprehensive liability
insurance and an aggregate of [ * ] in product liability insurance.

      9.4 Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT
OR OTHERWISE, NEITHER PARTY WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF
THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL
OR EQUITABLE THEORY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES OR LOST PROFITS.

10. REPRESENTATIONS AND WARRANTIES AND COVENANTS

      10.1 ImmunoGen. ImmunoGen represents and warrants to Millennium that: (a)
it has the full right, power and authority to enter into this Agreement and to
grant the rights and licenses granted by it hereunder; (b) to the knowledge of
ImmunoGen, there are no existing or threatened actions, suits or claims pending
with respect to the subject matter hereof or the right of ImmunoGen to enter
into and perform its obligations under this Agreement; (c) it has taken all
necessary action

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       26
<PAGE>

on its part to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder; (d) this Agreement has been duly
executed and delivered on behalf of it, and constitutes a legal, valid, binding
obligation, enforceable against it in accordance with the terms hereof; (e) the
execution and delivery of this Agreement and the performance of its obligations
hereunder do not conflict with or violate any requirement of applicable laws or
regulations and do not conflict with, or constitute a default under, any
contractual obligation of it; (f) upon its confirmation of the availability of
any Target Antigen designated by Millennium under Section 3.3 or 4.3 of this
Agreement, it will have the full right, power and authority to grant the
Exclusive Option or [ * ] to such Target Antigen upon the terms of this
Agreement and such grant will not conflict with, or constitute a default under,
any of its contractual obligations to Third Parties; (g) it has sufficient
capability and resources to fulfill the supply obligations set forth in Section
5 of this Agreement; (h) it has not been debarred, is not subject to a pending
debarrment, and will not use, in any capacity, in connection with the supply of
Cytotoxic Compound or AB-Cytotoxic Product under this Agreement any person or
entity that has been debarred pursuant to Section 306 of the Federal Food, Drug
and Cosmetic Act.

      10.2 Millennium. Millennium represents and warrants to ImmunoGen that: (a)
it has the full right, power and authority to enter into this Agreement and to
grant the licenses granted by it hereunder; (b) to the knowledge of Millennium,
there are no existing or threatened actions, suits or claims pending with
respect to the subject matter hereof or the right of Millennium to enter into
and perform its obligations under this Agreement; (c) it has taken all necessary
action on its part to authorize the execution and delivery of this Agreement and
the performance of its obligations hereunder; (d) this Agreement has been duly
executed and delivered on behalf of it, and constitutes a legal, valid, binding
obligation, enforceable against it in accordance with the terms hereof; and (e)
the execution and delivery of this Agreement and the performance of its
obligations hereunder do not conflict with or violate any requirement of
applicable laws or regulations and do not conflict with, or constitute a default
under, any contractual obligation of it.

      10.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR
VALIDITY OF TECHNOLOGY OR PATENT CLAIMS, WHETHER ISSUED OR PENDING.

      10.4 ImmunoGen [ * ]. ImmunoGen hereby [ * ] that during the period
commencing on the Effective Date and continuing for a period of [ * ]
thereafter, ImmunoGen shall not [ * ] which would [ * ], other than the grant by
ImmunoGen of [ * ]. Within [ * ] of notice from ImmunoGen of any [ * ] shall
have the [ * ] this [ * ] upon [ * ] upon [ * ] and [ * ] shall have [ * ] as of
[ * ], up to [ * ] in

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       27
<PAGE>

accordance [ * ] hereof; provided, that, notwithstanding anything to the
contrary contained in [ * ], Millennium shall be required to [ * ] as part of
the [ * ]. Nothing contained in [ * ] shall be deemed to limit [ * ] under this
Agreement. Notwithstanding any such [ * ] shall have the right to [ * ] as of
the date of [ * ] by it pursuant to this [ * ], and [ * ] as of the date of [ *
] in accordance with the terms for [ * ] and [ * ] set forth in this Agreement.

11. TERM AND TERMINATION

      11.1 Term. This Agreement shall commence on the Effective Date and, unless
terminated earlier pursuant to Section 11.6 of this Agreement, shall continue
until the expiration of [ * ] granted under this Agreement.

      11.2 Termination of Individual [ * ] by Millennium. Millennium shall have
the right to terminate an [ * ] for a particular Millennium Target Antigen at
any time by providing ImmunoGen [ * ] prior written notice of termination of
such [ * ]. Any such termination shall not effect the continuation of any other
Exclusive Option, [ * ] or this Agreement.

      11.3 Termination of Individual [ * ] for Breach. In the event that a Party
shall have breached or defaulted in the performance of any of its material
obligations under an [ * ] for a particular Millennium Target Antigen, and such
breach or default shall continue for a period of [ * ] after written notice of
such breach and the intent to terminate is provided to the breaching Party by
the non-breaching Party in the case of a payment breach and [ * ] after written
notice of such breach and the intent to terminate is provided to the breaching
Party by the non-breaching Party in the case of any other breach, the
non-breaching Party shall have the right, but not the obligation, to terminate
such [ * ] (and only such [ * ]) upon a second written notice to the breaching
Party. Any such termination shall not effect the continuation of any other
Exclusive Option, [ * ] or this Agreement.

      11.4 Accrued Obligations in Case of Termination of Individual [ * ].
Except as otherwise provided herein, termination of an [ * ] for a particular
Millennium Target Antigen shall not release either Party from any liability
which at the time of termination of such [ * ] has already accrued to the other
Party or which is attributable to a period prior to termination of such license,
nor preclude either Party from pursuing any rights and remedies it may have
hereunder or at law or in equity which accrued or are based upon events
occurring prior to termination of such [ * ].

      11.5 Product Inventory in Case of Termination of Individual [ * ]. In the
event an [ * ] for a particular Millennium Target Antigen is terminated for any
reason, [ * ] shall have the right, for a period of [ * ], to [ * ] of the [ * ]
and any [ * ] generated from [ * ] is the subject of such [ * ] in accordance
with the terms for such [ * ] set forth in this

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       28
<PAGE>

Agreement. Notwithstanding the foregoing, no termination of an [ * ] by
ImmunoGen under Section 11.3 of this Agreement shall be construed as a
termination of any valid sublicense of any sublicensee thereunder, and
thereafter each such sublicensee shall be considered a direct licensee of
ImmunoGen, provided, that, (a) such sublicensee is then in full compliance with
all terms and conditions of its sublicense, (b) all accrued payment obligations
to ImmunoGen have been paid, and (c) such sublicensee agrees at least [ * ]
prior to the effective date of such termination to assume all obligations of
Millennium under this Agreement pertaining to such [ * ].

      11.6 Termination of Agreement for Breach. In the event that a Party shall
have breached or defaulted in the performance of any of its material obligations
hereunder (other than a breach of an [ * ] for a particular Millennium Target
Antigen for which the terms of Section 11.3 of this Agreement shall apply), and
such breach or default shall continue for a period of [ * ] days after written
notice of such breach and the intent to terminate is provided to the breaching
Party by the non-breaching Party, the non-breaching Party shall have the right,
but not the obligation, to terminate this Agreement upon a second written notice
to the breaching Party. For the avoidance of doubt, the failure to provide
prompt notice under either Section 7.4 or 7.5 of this Agreement shall not
constitute the breach of a material obligation under this Agreement.

      11.7 Effect of Termination. Upon any termination of this Agreement, (a) as
of the effective date of such termination, all licenses granted by ImmunoGen to
Millennium under Sections 2 and 3 of this Agreement (and all related sublicenses
granted by Millennium) shall terminate and (b) Millennium shall have the right
to continue in effect, upon the terms and conditions set forth in this Agreement
and any related [ * ] entered into pursuant to Section 5.2 of this Agreement,
any [ * ] existing as of the effective date of termination under Section 11.6 of
this Agreement. Further, in the event that there shall be no [ * ] existing as
of the effective date of the termination under Section 11.6 of the Agreement,
Millennium shall, at the instruction of ImmunoGen, destroy or return any
ImmunoGen Materials in its possession as of the effective date of such
termination.

      11.8 Accrued Obligations in Case of Termination of Agreement. Except as
otherwise provided herein, termination of this Agreement for any reason shall
not release either Party from any liability which at the time of such
termination has already accrued to the other Party or which is attributable to a
period prior to such termination, nor preclude either Party from pursuing any
rights and remedies it may have hereunder or at law or in equity which accrued
are based upon events occurring prior to such termination of this Agreement.

      11.9 Survival. Sections 6, 7, 8, 9, 10, 11 and 12 of this Agreement shall
survive the termination of this Agreement for any reason.

12. MISCELLANEOUS

      12.1 Governing Laws. This Agreement shall be governed by, interpreted and
construed in accordance with the substantive laws of the Commonwealth of
Massachusetts, without regard to conflicts of law principles.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       29
<PAGE>

      12.2 Waiver. It is agreed that no waiver by any Party hereto of any breach
or default of any of the covenants or agreements herein set forth shall be
deemed a waiver as to any subsequent and/or similar breach or default.

      12.3 Assignments. Neither this Agreement nor any right or obligation
hereunder may be assigned or delegated, in whole or part, by either Party
without the prior written consent of the other; provided, however, that either
Party may, without the written consent of the other, assign this Agreement and
its rights and delegate its obligations hereunder in connection with the
transfer or sale of all or substantially all of its business or in the event of
its merger, consolidation, change in control or similar transaction. Any
permitted assignee shall assume all obligations of its assignor under this
Agreement. Any purported assignment in violation of this Section 12.3 shall be
void.

      12.4 Independent Contractors. The relationship of the Parties hereto is
that of independent contractors. The Parties hereto are not deemed to be agents,
partners or joint ventures of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby.

      12.5 Notices. All requests and notices required or permitted to be given
to the parties hereto shall be given in writing, shall expressly reference the
section(s) of this Agreement to which they pertain, and shall be delivered to
the other Party at the appropriate address as set below in the first paragraph
of this Agreement or to such other addresses as may be designated in writing by
the parties from time to time during the term of this Agreement.

If to ImmunoGen:

ImmunoGen Inc.
128 Sidney Street
Cambridge, Massachusetts 02139
Attn: Chief Executive Officer

With a copy to:

Mintz, Levin, Cohn, Ferris, Glovsky
  and Popeo, P.C.
One Financial Center
Boston, MA 02111
Attn: Jeffrey M. Wiesen, Esq
Telecopy: 617-542-2241

If to Millennium:

Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       30
<PAGE>

Attn: Chief Business Officer

With a copy to:

Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139
Attn: General Counsel

Delivery shall be by hand, by certified mail, postage prepaid, return receipt
requested, or by a recognized overnight courier. Requests and notices shall be
deemed received on the date of delivery in the case of hand delivery, three days
subsequent to mailing in the case of certified mail, and on the date of delivery
in the case of overnight courier.

      12.6 Force Majeure. Nonperformance of any Party shall be excused to the
extent that performance is rendered impossible by strike, fire, earthquake,
flood, governmental acts or orders or restrictions, failure of suppliers, or any
other reason where failure to perform, is beyond the reasonable control and not
caused by the negligence, intentional conduct or misconduct of the nonperforming
Party.

      12.7 Disputes.

            (a) The Parties recognize that a bona fide dispute as to certain
matters may from time to time arise during the term of this Agreement which
relates to either Party's rights and/or obligations hereunder. In the event of
the occurrence of such a dispute, either Party may, by written notice to the
other Party, have such dispute referred to their respective senior officials
designated below, or their designees of comparable seniority, for attempted
resolution by good faith negotiations within [ * ] after such notice is
received. Said designated senior officials are as follows:

For Millennium: Chief Business Officer

For ImmunoGen:  Chief Executive Officer

In the event the designated senior officials are not able to resolve such
dispute within the [ * ] period, either Party may invoke the provisions of
Section 12.7(b) of this Agreement.

            (b) Any dispute, controversy or claim initiated by either Party
arising out of, resulting from or relating to this Agreement, or the performance
by either Party of its obligations under this Agreement (other than bona fide
third party actions or proceedings filed or instituted in an action or
proceeding by a Third Party against a Party), whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration.
Whenever a Party shall decide to institute arbitration proceedings, it shall
give written notice to that effect to the other Party. Any such arbitration
shall be conducted under the Commercial Arbitration Rules of the American

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       31
<PAGE>

Arbitration Association by a panel of three arbitrators appointed in accordance
with such rules. Any such arbitration shall be held in Boston, Massachusetts.
The arbitrators shall have the authority to grant specific performance and to
allocate between the parties the costs of arbitration in such equitable manner
as they determine. Judgment upon the award so rendered may be entered in any
court having jurisdiction or application may be made to such court for judicial
acceptance of any award and an order of enforcement, as the case may be. In no
event shall a demand for arbitration be made after the date when institution of
a legal or equitable proceeding based upon such claim, dispute or other matter
in question would be barred by the applicable statute of limitations.
Notwithstanding the foregoing, either Party shall have the right, without
waiving any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any
interim or provisional relief that is necessary or desirable to protect the
rights or property of such Party, pending the selection of the arbitrators
hereunder or pending the arbitrators' determination of any dispute, controversy
or claim hereunder.

      12.8 Complete Agreement. It is understood and agreed between ImmunoGen and
Millennium that this Agreement constitutes the entire agreement, both written
and oral, between the parties with respect to the subject matter hereof, and
that all prior agreements respecting the subject matter hereof, including the
Evaluation Agreement, either written or oral, expressed or implied, shall be of
no force or effect. No amendment or change hereof or addition hereto shall be
effective or binding on either of the parties hereto unless reduced to writing
and executed by the respective duly authorized representatives of ImmunoGen and
Millennium.

      12.9 Severability. In the event that any provisions of this Agreement are
determined to be invalid or unenforceable by a court of competent jurisdiction,
the remainder of the Agreement shall remain in full force and effect without
such provision. In such event, the parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the parties in entering this
Agreement.

      12.10 Counterparts. This Agreement may be executed in counterparts, each
of which shall be deemed to be an original and both together shall be deemed to
be one and the same agreement.

      12.11 Construction. The Parties hereto acknowledge and agree that: (a)
each Party and its counsel reviewed and negotiated the terms and provisions of
this Agreement and have contributed to its revision; (b) the rule of
construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement;
and (c) the terms and provisions of this Agreement shall be construed fairly as
to each Party hereto an not in a favor of or against any Party, regardless of
which Party was generally responsible for the preparation of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       32
<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Agreement as a sealed
document, through their respective officers hereunto duly authorized, as of the
day and year first above written.

                                        IMMUNOGEN, INC.

                                        By: ____________________________________
                                              Name:
                                              Title:

                                        MILLENNIUM PHARMACEUTICALS, INC.

                                        By: ____________________________________
                                              Name:
                                              Title:

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       33
<PAGE>

                                  Attachment A

                            IMMUNOGEN PATENT RIGHTS

[ * ]

--------------------------------------------------------------------------------
Attorney   Country   Appl. No.  Filing    Priority   Patent No.   Issue    Exp.
Reference                       Date      Date                    Date
No.
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]                [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]
                     [ * ]      [ * ]     [ * ]      [ * ]        [ * ]    [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]
                     [ * ]      [ * ]     [ * ]      [ * ]        [ * ]    [ * ]
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]        [ * ]    [ * ]
--------------------------------------------------------------------------------
           [               *                  ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [        *       ]
--------------------------------------------------------------------------------

[ * ]

--------------------------------------------------------------------------------
Attorney   Country   Appl. No.  Filing    Priority   Patent No.   Issue    Exp.
Reference                       Date      Date                    Date     Date
No.
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]                [ * ]
--------------------------------------------------------------------------------

[ * ]

--------------------------------------------------------------------------------
Attorney   Country   Appl. No.  Filing    Priority   Patent No.   Issue    Exp.
Reference                       Date      Date                    Date     Date
No.
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]
--------------------------------------------------------------------------------

[ * ]

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       34
<PAGE>

--------------------------------------------------------------------------------
Attorney   Country   Appl. No.  Filing    Priority   Patent No.   Issue    Exp.
Reference                       Date      Date                    Date     Date
No.
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]                [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]                                     [ * ]
                     [ * ]      [ * ]     [ * ]                   [ * ]    [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]                                     [ * ]
                     [ * ]      [ * ]     [ * ]                   [ * ]    [ * ]
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
[ * ]      [ * ]
                     [ * ]      [ * ]     [ * ]      [ * ]        [ * ]    [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]        [ * ]    [ * ]
--------------------------------------------------------------------------------
           [               *                  ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [        *       ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [        *       ]
--------------------------------------------------------------------------------

[ * ]

--------------------------------------------------------------------------------
Attorney   Country   Appl. No.  Filing    Priority   Patent No.   Issue    Exp.
Reference                       Date      Date                    Date     Date
No.
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]
                                                     [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]
--------------------------------------------------------------------------------

[ * ]

--------------------------------------------------------------------------------
Attorney   Country   Appl. No.  Filing    Priority   Patent No.   Issue    Exp.
Reference                       Date      Date                    Date     Date
No.
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]
--------------------------------------------------------------------------------
[ * ]      [ * ]     [ * ]      [ * ]     [ * ]      [ * ]
--------------------------------------------------------------------------------

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       35
<PAGE>

                                  Attachment B

                                      [ * ]

A. Specifications provided for research use [ * ]

--------------------------------------------------------------------------------
    Testing                     Method               Target Specifications
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                                        [            *         ]
                               [   *  ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------

B. Additional Specifications provided for use of [ * ]

--------------------------------------------------------------------------------
    Testing                     Method               Target Specifications
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------
   [   *   ]                   [   *  ]             [            *         ]
--------------------------------------------------------------------------------

(a) [ * ]

(b) [ * ]

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       36
<PAGE>

                                  Attachment C

                         Provisions for [ * ] Agreements

All [ * ] will include:

o     Systems for [ * ]

o     Specifications for [ * ] as are [ * ].

o     Requirement for [ * ] using, or in accordance and/or compliance with, [ *
      ] as are [ * ] by the Parties in the [ * ].

o     Requirement that [ * ] be [ * ] by [ * ] in accordance with such quality
      control and quality assurance analyses and procedures as [ * ] in the [ *
      ].

o     [ * ] that, at the time [ * ] shall have been [ * ].

o     [ * ]

o     [ * ]

o     [ * ]

o     [ * ]

o     [ * ]

o     [ * ]

o     [ * ]

o     [ * ]

o     [ * ].

o     [ * ]

o     [ * ].

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       37
<PAGE>

--------------------------------------------------------------------------------
TRA 1511167v5
--------------------------------------------------------------------------------

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.

                                       38

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]